University College London - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Market Overview

Summary

University College London (UCL), a subsidiary of University of London is an educational institute that provides undergraduate, post-graduate, and life learning programs. The institute offers programs in the areas of arts and humanities, Bartlett faculty of the built environment, brain sciences, engineering, laws, life sciences, mathematical and physical sciences, medical sciences, population health sciences and social, and historical sciences. Its services include alumini services, infrastructure management, finance and business affairs, human resource development, information services, library services, public and cultural engagement, and student and registry services. The institute conducts research in partnership with other research organisations, commerce and industry, and healthcare providers. UCL is headquartered in London, the UK.

University College London-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Scope

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

University College London, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

University College London, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

University College London, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

University College London, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

University College London, Medical Devices Deals, 2012 to YTD 2018 11

University College London, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

University College London, Pharmaceuticals & Healthcare, Deal Details 16

Venture Financing 16

Orchard Therapeutics Raises USD31 Million in Series A Venture Financing 16

Puridify Raises USD3.4 Million in Series A Financing 17

Autifony Therapeutics Raises USD12.3 Million in Extended Series A Financing 18

Puridify Raises USD1.43 Million in Seed Funding 19

Canbex Therapeutics Raises USD 3 Million In Venture Financing 20

Domainex Raises Funds In First Tranche Of USD 2.3 Million Venture Financing Round 21

Partnerships 22

Synpromics Enters into Co-Development Agreement with University College London 22

Sygnature Discovery and UCL School of Pharmacy Enter into Research Partnership 23

Tusk Therapeutics Enters into Agreement with University College London and Cancer Research Technology 24

Cell Medica Enters into Partnership with University College London 25

Santen Pharma to Enter into Agreement with University College London 26

Orchard Therapeutics Enters into Co-Development Agreement for Transformative Gene Therapies 27

Teva Pharma Partners with University College London and Imanova 29

University College London Enters into Research Agreement with Takeda Pharma 30

Magnus Life Science Partners with University College London 31

UCL Business Forms Joint Venture with Syncona 32

Chiesi Farmaceutici Enters into Agreement With University College London 33

Cell Therapy Catapult Forms Catapult Therapy TCR with UCL Business and Imperial Innovations 34

Cambridge University, Imperial College London, King's College London, Queen Mary University London, University College London and Oxford University Enter into Research and Development Agreement with Pfizer 35

Nanomerics, University College London and Lundbeck Enter Collaboration Agreement 37

Takeda Enters into R&D Agreement with University College London 38

iQur Enters into Co-Development Agreement with Six Consortium 39

Almac Enters Into Co-Development Agreement With University College London For Metagenomics, Enzyme Discovery Tools 40

Cellectis Enters Into Co-Development Agreement With University College London 41

Eisai Enters Into Drug Discovery Agreement With University College London For Neurological Drugs 42

Sarepta Therapeutics Enters Into Co-Development Agreement With University College London 43

Horizon Discovery Enters Into R&D Agreement With UCL Institute of Neurology For rAAV-mediated Genome Editing 44

TAP Biosystems Enters Into Co-Development Agreement With University College London 45

Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 46

Licensing Agreements 48

Autolus Enters into Licensing Agreement with UCL Business 48

MeiraGTx Enters into Licensing Agreement with UCL Business 49

TC BioPharm Enters into Licensing Agreement with University College London 50

MeiraGTx Enters into Licensing Agreement with UCL Business 51

Tusk Therapeutics Enters into Licensing Agreement with University College London and Cancer Research Technology 52

Achilles Therapeutics Receives Rights to Develop Immunotherapies for Cancer 53

Autolus Amends Licensing Agreement with UCL Business 54

BioKier Enters into Licensing Agreement with UCL Business 55

Oxford Pharmascience Extends Licensing Agreement With UCL Business 56

Achilles Therapeutics Enters into Licensing Agreement with University College London and Francis Crick Institute 57

Antitope Enters into Licensing Agreement with University College London for Humanized Antibodies 58

BioMarin Pharma Enters Into Licensing Agreement With University College London And St. Jude Children's Research Hospital For Hemophilia A Gene Therapy Program 59

Oxford Pharmascience Enters Into Licensing Agreement With UCL Business For Drug Delivery Technology 61

University College London Business Enters Into Licensing Agreement With TAP Biosystems For RAFT Technology 62

Equity Offering 63

Autolus Spin Out from University College London 63

Nanomerics Spin Out from University College London 64

Puridify Spin Out from University College London 65

Asset Transactions 66

Freeline Therapeutics Acquires Intellectual Property Rights from UCL 66

University College London-Key Competitors 67

University College London-Key Employees 68

University College London-Locations And Subsidiaries 69

Head Office 69

Other Locations & Subsidiaries 69

Joint Venture 70

Recent Developments 72

Government and Public Interest 72

Sep 07, 2018: Research trial aims to reduce major cause of birth disabilities 72

Aug 29, 2018: Rapid heart imaging technique may cut costs, boost care in developing world 73

Jul 26, 2018: UK and India join forces to tackle the global health needs of women and children 74

Jul 24, 2018: First randomised trial of 'kick and kill' approach to HIV cure leaves puzzles to be solved 76

Jun 14, 2018: Scientists unravel molecular mechanisms of Parkinson's disease 77

May 10, 2018: GBP4m bid to find therapies that prompt tissues to repair 78

Mar 12, 2018: MRC secures GBP40million for new UK Dementia Research Institute (UK DRI) building 79

Feb 13, 2018: North-south divide revealed as prescription of opioid drugs rise 80

Feb 06, 2018: Major research project launched to crack aspirin's anti-cancer properties 81

Jan 24, 2018: Synthetic Virus to Tackle Antimicrobial Resistance 82

Nov 16, 2017: New talking therapy could help cancer survivors cope after treatment 83

Nov 15, 2017: Improving clinical trials with machine learning 84

Nov 03, 2017: More women than men are diagnosed with bowel cancer as an emergency despite extra GP visits 85

Sep 05, 2017: Acceptance and Commitment Therapy for people with motor neuron disease 86

Aug 18, 2017: GBP5 million for new NIHR Obesity Policy Research Unit 87

Aug 17, 2017: MRC researchers win prestigious awards for contribution to neurodegeneration research 88

Apr 04, 2017: Common antibiotic may help to prevent or treat PTSD 89

Mar 31, 2017: A better way to find drug targets 90

Mar 02, 2017: Abzena, UCL secure GBP3.5m grant from MRC for autoimmune therapy research 91

Product News 92

Oct 12, 2017: New drug hope for patients with rare bone cancer 92

Sep 13, 2018: Blood and brain fluid change first in Huntington's disease 93

May 09, 2017: Trial to investigate if statins could become multiple sclerosis treatment 94

Feb 01, 2017: Researchers develop best-yet cell culture system for age-related macular degeneration 95

Other Significant Developments 96

Sep 10, 2018: New method of pinpointing cancer mutations could lead to more targeted treatments 96

Aug 08, 2018: Ethnic differences in dementia diagnosis in the UK 98

Appendix 99

Methodology 99

About GlobalData 99

Contact Us 99

Disclaimer 99


List Of Figure

List of Figures

University College London, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

University College London, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

University College London, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

University College London, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

University College London, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

University College London, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

University College London, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

University College London, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

University College London, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

University College London, Pharmaceuticals & Healthcare, Key Facts 2

University College London, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

University College London, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

University College London, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

University College London, Deals By Therapy Area, 2012 to YTD 2018 10

University College London, Medical Devices Deals, 2012 to YTD 2018 11

University College London, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Orchard Therapeutics Raises USD31 Million in Series A Venture Financing 16

Puridify Raises USD3.4 Million in Series A Financing 17

Autifony Therapeutics Raises USD12.3 Million in Extended Series A Financing 18

Puridify Raises USD1.43 Million in Seed Funding 19

Canbex Therapeutics Raises USD 3 Million In Venture Financing 20

Domainex Raises Funds In First Tranche Of USD 2.3 Million Venture Financing Round 21

Synpromics Enters into Co-Development Agreement with University College London 22

Sygnature Discovery and UCL School of Pharmacy Enter into Research Partnership 23

Tusk Therapeutics Enters into Agreement with University College London and Cancer Research Technology 24

Cell Medica Enters into Partnership with University College London 25

Santen Pharma to Enter into Agreement with University College London 26

Orchard Therapeutics Enters into Co-Development Agreement for Transformative Gene Therapies 27

Teva Pharma Partners with University College London and Imanova 29

University College London Enters into Research Agreement with Takeda Pharma 30

Magnus Life Science Partners with University College London 31

UCL Business Forms Joint Venture with Syncona 32

Chiesi Farmaceutici Enters into Agreement With University College London 33

Cell Therapy Catapult Forms Catapult Therapy TCR with UCL Business and Imperial Innovations 34

Cambridge University, Imperial College London, King's College London, Queen Mary University London, University College London and Oxford University Enter into Research and Development Agreement with Pfizer 35

Nanomerics, University College London and Lundbeck Enter Collaboration Agreement 37

Takeda Enters into R&D Agreement with University College London 38

iQur Enters into Co-Development Agreement with Six Consortium 39

Almac Enters Into Co-Development Agreement With University College London For Metagenomics, Enzyme Discovery Tools 40

Cellectis Enters Into Co-Development Agreement With University College London 41

Eisai Enters Into Drug Discovery Agreement With University College London For Neurological Drugs 42

Sarepta Therapeutics Enters Into Co-Development Agreement With University College London 43

Horizon Discovery Enters Into R&D Agreement With UCL Institute of Neurology For rAAV-mediated Genome Editing 44

TAP Biosystems Enters Into Co-Development Agreement With University College London 45

Cancer Research Technology Enters Into Co-Development Agreement With ADC Therapeutics For Antibody Drug Conjugates 46

Autolus Enters into Licensing Agreement with UCL Business 48

MeiraGTx Enters into Licensing Agreement with UCL Business 49

TC BioPharm Enters into Licensing Agreement with University College London 50

MeiraGTx Enters into Licensing Agreement with UCL Business 51

Tusk Therapeutics Enters into Licensing Agreement with University College London and Cancer Research Technology 52

Achilles Therapeutics Receives Rights to Develop Immunotherapies for Cancer 53

Autolus Amends Licensing Agreement with UCL Business 54

BioKier Enters into Licensing Agreement with UCL Business 55

Oxford Pharmascience Extends Licensing Agreement With UCL Business 56

Achilles Therapeutics Enters into Licensing Agreement with University College London and Francis Crick Institute 57

Antitope Enters into Licensing Agreement with University College London for Humanized Antibodies 58

BioMarin Pharma Enters Into Licensing Agreement With University College London And St. Jude Children's Research Hospital For Hemophilia A Gene Therapy Program 59

Oxford Pharmascience Enters Into Licensing Agreement With UCL Business For Drug Delivery Technology 61

University College London Business Enters Into Licensing Agreement With TAP Biosystems For RAFT Technology 62

Autolus Spin Out from University College London 63

Nanomerics Spin Out from University College London 64

Puridify Spin Out from University College London 65

Freeline Therapeutics Acquires Intellectual Property Rights from UCL 66

University College London, Key Competitors 67

University College London, Key Employees 68

University College London, Subsidiaries 69

University College London, Joint Venture 70

You can also purchase parts of this report. Do you want to check out a section wise price list?
Thank You for submiting the form our team will reach you withing next 24 hours.
85% of our clients seek customized reports. How do you wish us to custom yours?


Products

Products

University College London, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Testimonial

Industry Speak